TGTX
TG THERAPEUTICS, INC.
Next earnings Aug 3, 2026 · consensus $0.36 EPS, $233M rev
Last earnings +16.3% on 2026-05-06
$55.83
▲ +4.10%$55.83▲ +52.71%
over 1Y
L $26.39EODHDH $55.83
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.1%
1W+2.6%
1M+42.4%
3M+75.8%
YTD+90.7%
1Y+52.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy
BRIUMVI is ramping fast (+87% revenue), but the headline profit is tax-inflated and the stock trades at 13.8x sales.
Revenue $616M · FY2025
The read
Middling fundamentals offset by an attractive price (~89% below fair value) — worth a look on the value angle.
TG Therapeutics has a genuine commercial success in BRIUMVI (ublituximab), an anti-CD20 antibody for relapsing MS whose one-hour, twice-yearly infusion is a real convenience differentiator. The launch is scaling impressively: FY2025 revenue jumped 87.3% to $616M (from $234M in FY2023, the first commercial year), and an ex-US commercialization deal with Neuraxpharm adds milestone, royalty and supply revenue. Operating income turned solidly positive at $123M (20.0% operating margin), a real inflection for a former cash-burning biotech.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $6.69M | $2.79M | $234M | $329M | $616M |
| Gross profit | — | — | — | — | — |
| Operating income | -$345M | -$218M | $20.6M | $41.9M | $123M |
| Net income | -$348M | -$224M | $12.7M | $23.4M | $447M |
| Diluted EPS | -$2.63 | -$1.65 | $0.09 | $0.15 | $2.77 |
| Net margin | -5204.1% | -8036.3% | 5.4% | 7.1% | 72.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$9.08B
EV / EBITDA73.6
EV / Sales14.7
EV / FCF—
P / FCF—
PEG (trailing)0.01
Earnings yield5.0%
FCF yield-0.3%
Quality & risk
ROIC (est.)10.9%
Free cash flow-$25.0M
Total debt$246M
Net cash-$166M
Altman Z-Score12.96 safe
Piotroski F-Score4/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+1.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗8-KPeriod ending 2026-06-112026-06-12open ↗8-KPeriod ending 2026-06-032026-06-03open ↗8-KPeriod ending 2026-05-272026-05-27open ↗10-QPeriod ending 2026-03-312026-05-06open ↗8-KPeriod ending 2026-05-062026-05-06open ↗DEF 14APeriod ending 2026-06-112026-04-30open ↗SCHEDULE 13GFiling2026-04-29open ↗
Frequently asked
- Is TG THERAPEUTICS, INC. (TGTX) a buy?
- TGTX currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. BRIUMVI is ramping fast (+87% revenue), but the headline profit is tax-inflated and the stock trades at 13.8x sales.
- What is TGTX's fair value?
- A Modified-Graham model based on TGTX's SEC fundamentals estimates a fair value of about $105.26. It is an estimate from reported earnings, not a price target.
- Is TGTX overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, TGTX currently appears undervalued relative to its SEC-grounded earnings power.
- What is TG THERAPEUTICS, INC.'s quality score?
- TGTX scores 80.80392156862744/100 (grade A-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001001316, latest 10-Q filed 2026-05-06) · EODHD · analysis by claude-code · as of 6/21/2026, 8:52:25 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.